SOUTH SAN FRANCISCO, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced the launch of its inaugural Proteomics Roundtable Series – a program of virtual events designed to spark conversation about the rapidly evolving field of proteomics. The series will spotlight thought leaders and industry experts discussing groundbreaking research, technological advancements and real-world applications of proteomics shaping the future of healthcare.

The first session will be:

Is More Really More? Evaluating the Case for High-Plex, High-Quality Proteomics
Friday, June 6, 2025 – 11:00 am ET

Stephen Williams, MD, PhD, Chief Medical Officer at Standard BioTools will host a panel featuring investigators from the 30-year, 500,000-participant EPIC cancer study. These researchers will explain how they found “black swan” insights into the development of major cancers from proteins previously unmeasurable across massive cohorts. Speakers for this session include:

• Elio Riboli, MD – Professor of Cancer Epidemiology, Imperial College London
• Marc Gunter, PhD – Professor and Chair in Cancer Epidemiology and Prevention, Imperial College London
• Karl Smith-Byrne, DPhil – Senior Molecular Epidemiologist, University of Oxford

Register for this event: https://my.demio.com/ref/R0G9BWrKddIDAJmO

Upcoming topics for future Proteomics Roundtable events include the following:

Quantifying Confidence: Comparative Metrics for Proteomic Platforms that Matter

In this session, leading proteomics researchers will dive into differentiators in proteomics. From dispelling cross-reactivity myths to explaining head-to-head data, learn how researchers evaluate technologies for massive-scale studies.

Trusted at Scale: Deployment of Proteomic Technologies in Biobanks

Find out how leading biobank researchers are translating large-scale proteomic data into real-world insights. As biobank investigators work to advance research across diverse populations, platform choice becomes mission-critical and focused on balancing throughput, reproducibility and depth of measurement.

Accelerating Drug Development: Proteomics in Clinical Trials

Top biopharma innovators are using the SomaScan™ Assay to accelerate decision making and de-risk drug development, while getting closer to patients. Researchers will discuss how proteomics is delivering the insights they need to find better drugs, faster.

Registration & Participation:

Individuals interested in attending these virtual events can register via the Standard BioTools website at https://www.standardbio.com/2025-proteomics-roundtable where future updates will also be provided. These sessions will be webcast on the Investor page of the Company’s website and will be available for replay.

About Standard BioTools Inc. 

Standard BioTools Inc. (Nasdaq: LAB), has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary SomaScan, mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook and LinkedIn.

For Research Use Only. Not for use in diagnostic procedures.

Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms
Patent and License Information: standardbio.com/legal/notices.
Trademarks: standardbio.com/legal/trademarks.
Any other trademarks are the sole property of their respective owners.
©2025 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.

Media Contact                                
Emilia Costales                                
This email address is being protected from spambots. You need JavaScript enabled to view it.                

Investor Contact
This email address is being protected from spambots. You need JavaScript enabled to view it.